Skip to main content
. 2018 Feb 14;34(1):63–73. doi: 10.1093/ndt/gfx378

FIGURE 4.

FIGURE 4

Case–control analysis with propensity-matched patients from EUVAS trials. Cox proportional hazards regression models. (A) The adjusted all-cause mortality, (B) ESRD and (C) relapse risk between the EUVAS cohort and combined treatment (‘CycLowVas’) cohort. The covariates in the analysis include age, sex, ANCA specificity, entry eGFR, entry BVAS and dose of cyclophosphamide.